Cryo-Save Group N.V. - Cord blood sample release for stem cell transplantation
(Thomson Reuters ONE) -
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading
international stem cell storage company and the largest family stem cell bank in
Europe, announced a stem cell transplantation in Spain to treat Blackfan-Diamond
Aneamia. It is the first time in Spain that this congenital anaemia, classified
as a rare disease, has been treated using cord blood stem cells which were
stored with Cryo-Save.
A 4-year-old boy was treated for Blackfan-Diamond anaemia (BDA) with a stem cell
transplant from his sister's umbilical cord blood. The transplant was performed
on April 25 at the Hospital del Niño Jesús in Madrid, one of the most important
paediatric hospitals in Spain.
The transplantation was successful, and the child is expected to make a normal
recovery. This pioneering treatment in Spain may herald a radical improvement in
the child's quality of life, as since birth he has required regular red blood
cell transfusions.
"Up until the transplantation our life was bound to red blood cell transfusions.
We could hardly be happier, because now our son will be able to lead a
completely normal life", said Elena, the boy's mother. The parents had only
found out about the possibility of this type of treatment when Elena was
pregnant with her daughter, now the cord blood donor. "We had the opportunity to
heal our son, if the sample was compatible, and we could not forego it", she
said. "Our daughter will be very happy when she learns that her brother got
better thanks to her", she added.
"Blackfan-Diamond anaemia is a congenital disease that prevents the bone marrow
from producing the red blood cells needed to carry oxygen throughout the body",
explained Dr. Luis Madero, Head of the Oncohaematology Department of the
Hospital Niño Jesús in Madrid, and the physician who performed the
transplantation. Until recently, the main treatments were periodical red blood
cell transfusions, which clearly affects the patient's quality of life, and
long-term corticosteroid therapy, which is not tolerated in all cases. "The
transplantation of umbilical cord blood stem cells, especially between siblings,
is now a recommended treatment option for certain types of haematological
diseases, such as BDA. The benefits versus other treatments for this disease are
clear and confirmed by several studies", asserted Dr. Madero.
Arnoud van Tulder, Chief Executive officer, commented:
"We are very proud and pleased to have contributed to alleviating this family's
suffering. Cryo-Save strives to serve society by offering the highest quality in
stem cell cryopreservation and supporting innovative stem cell therapies that
could save lives and improve the quality of life of patients.
"This successful stem cell transplantation is another example of the
implementation of our mission, the quality of our internal procedures and
underlines the importance of storing umbilical cord blood stem cells for
potential family needs."
Enquiries:
Cryo-Save Group, Arnoud van Tulder, Chief Executive Officer, + 31 (0)
575 509 100
Please click here for full press release in PDF:
http://hugin.info/143308/R/1697135/559150.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cryo-Save Group N.V. via Thomson Reuters ONE
[HUG#1697135]
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2013 - 10:00 Uhr
Sprache: Deutsch
News-ID 253689
Anzahl Zeichen: 4061
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cryo-Save Group N.V. - Cord blood sample release for stem cell transplantation"
steht unter der journalistisch-redaktionellen Verantwortung von
Cryo-Save Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
